Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Davila

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Cell|November 6, 2018
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent MetabolismMarc O Johnson, Melissa M Wolf, Matthew Z Madden, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Nature Medicine|January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activityArnab Ghosh, Melody Smith, Scott E James, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Science Translational Medicine|February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaMarco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Cell|November 6, 2018
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent MetabolismMarc O Johnson, Melissa M Wolf, Matthew Z Madden, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Nature Medicine|January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activityArnab Ghosh, Melody Smith, Scott E James, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Science Translational Medicine|February 21, 2014
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaMarco L Davila, Isabelle Riviere, Xiuyan Wang, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Pageof 13